National Catholic Reporter

The Independent News Source

Execution stopped over secrecy in Missouri’s lethal injection method

 |  NCR Today

The U.S. Supreme court order a stay in the execution of Missouri death row inmate Herbert Smulls late Tuesday night, two-and-a-half hours before Smulls was to be executed.

According to the Associated Press:

Smulls' lawyer, Cheryl Pilate, made last-minute pleas Tuesday to spare his life, focusing on the state's refusal to disclose the name of the compounding pharmacy that produces the lethal-injection drug, pentobarbital, for use in the execution. But Missouri has argued that the compounding pharmacy is part of the execution team and therefore its name cannot be released to the public.

07-04-2014.jpgThere's more to NCR than what you read online. Subscribe today!

Pilate contends that the state's secrecy makes it impossible to know whether the drug could cause pain and suffering during the execution process.

There is also a question over whether the state followed proper storage requirements for the drug.

NCR Comment code: (Comments can be found below)

Before you can post a comment, you must verify your email address at Disqus.com/verify.
Comments from unverified email addresses will be deleted.

  • Be respectful. Do not attack the writer. Take on the idea, not the messenger.
  • Don't use obscene, profane or vulgar language.
  • Stay on point. Comments that stray from the original idea will be deleted. NCR reserves the right to close comment threads when discussions are no longer productive.

We are not able to monitor every comment that comes through. If you see something objectionable, please click the "Report abuse" button. Once a comment has been flagged, an NCR staff member will investigate.

For more detailed guidelines, visit our User Guidelines page.

For help on how to post a comment, visit our reference page.

 

Feature-flag_GSR_start-reading.jpg

NCR Email Alerts

 

In This Issue

July 4-17, 2014

07-04-2014.jpg

Not all of our content is online. Subscribe to receive all the news and features you won't find anywhere else.